Archives
SAR405: Selective Vps34 Inhibitor for Autophagy Research
SAR405: Selective Vps34 Inhibitor for Autophagy Research
Executive Summary: SAR405 is a highly selective, nanomolar-potency ATP-competitive inhibitor of Vps34, a class III PI3K crucial for autophagy and vesicle trafficking (APExBIO product info). It inhibits human recombinant Vps34 with an IC50 of 1 nM and displays a dissociation constant (Kd) of 1.5 nM, showing minimal activity against class I/II PI3Ks or mTOR up to 10 μM. SAR405 disrupts the formation of phosphatidylinositol 3-phosphate (PtdIns3P) and autophagosomes, leading to lysosomal dysfunction, as confirmed by the accumulation of swollen late endosome-lysosomes and defective cathepsin D maturation. Its robust selectivity and compatibility with cellular assays position SAR405 as a gold-standard tool for probing autophagy inhibition, vesicle trafficking modulation, and synergistic effects with mTOR inhibitors (Park et al., 2023).
Biological Rationale
Autophagy is a conserved cellular process that maintains homeostasis during nutrient deprivation or energy stress (Park et al., 2023). Vps34, the sole class III PI3K, plays a central role in autophagosome initiation by generating PtdIns3P at autophagic membranes. Pharmacological inhibition of Vps34 provides a direct method to dissect autophagy pathways independently of upstream regulators such as AMPK or mTOR. Recent evidence indicates that the AMPK-ULK1-Vps34 axis is more complex than previously understood, with AMPK restraining rather than activating autophagy under energy stress (related article). This updated mechanistic insight underscores the importance of using highly selective tools like SAR405 to study autophagy inhibition without off-target effects on parallel signaling pathways.
Mechanism of Action of SAR405
SAR405 is an ATP-competitive Vps34 inhibitor that binds the ATP-binding cleft of Vps34 with nanomolar affinity (APExBIO). It prevents the kinase from phosphorylating phosphatidylinositol, thereby blocking the synthesis of PtdIns3P—a lipid essential for autophagosomal membrane nucleation and vesicle trafficking. This action disrupts autophagosome formation, leading to the accumulation of swollen late endosome-lysosome compartments and impaired cathepsin D maturation, indicating compromised lysosomal function (contrast: SAR405 focus on trafficking). SAR405 does not affect early endocytosis or Akt phosphorylation, further demonstrating its specificity for Vps34 over other PI3K isoforms and mTOR (related article).
Evidence & Benchmarks
- SAR405 exhibits an IC50 of 1 nM and Kd of 1.5 nM against human recombinant Vps34, indicating high potency and tight binding (APExBIO).
- No significant inhibition of class I/II PI3Ks or mTOR observed up to 10 μM, supporting its selectivity (SAR405 selectivity review).
- SAR405 treatment leads to defective autophagosome formation and lysosomal dysfunction as measured by cathepsin D maturation in cellular models (Park et al., 2023).
- Compatible with GFP-FYVE HeLa and GFP-LCLC3 cell lines, enabling robust quantification of autophagy inhibition and vesicle trafficking changes (cellular workflow article).
- SAR405 is DMSO soluble (>22 mg/mL) and ethanol soluble (>32 mg/mL, ultrasonication), but insoluble in water (APExBIO).
- Synergistic effects are observed when combined with mTOR inhibitors such as everolimus in cancer cell models (SAR405-mTOR synergy).
Applications, Limits & Misconceptions
SAR405, provided by APExBIO, is extensively used in autophagy research, cancer biology, and studies of vesicle trafficking modulation. Its nanomolar potency and selectivity make it suitable for dissecting the Vps34 kinase signaling pathway in cellular and translational models (APExBIO). Researchers leverage SAR405 to clarify the roles of autophagy inhibition in cancer cell survival, lysosome function impairment, and neurodegenerative disease models (previous SAR405 focus). This article extends prior reports by integrating new evidence that AMPK suppresses, rather than promotes, autophagy under energy stress, which may impact the interpretation of SAR405 effects in metabolic or stress paradigms (contrast: updated AMPK mechanism).
Common Pitfalls or Misconceptions
- Not a pan-PI3K inhibitor: SAR405 shows minimal activity against class I/II PI3Ks or mTOR, so it cannot be used as a general PI3K pathway blocker (APExBIO).
- Does not inhibit early endocytosis: SAR405 selectively targets late endosome-lysosome compartments, leaving early endocytic processes intact.
- Not suitable for aqueous solutions: SAR405 is insoluble in water; improper solvent choice can lead to precipitation and loss of activity.
- Autophagy inhibition context: Its effects may be misinterpreted if not considering the recent evidence that AMPK can suppress autophagy under energy stress (Park et al., 2023).
- Storage limitations: Stock solutions are not recommended for long-term storage once dissolved; always prepare fresh aliquots for reproducibility.
Workflow Integration & Parameters
- Solubility: Dissolve SAR405 in DMSO (>22 mg/mL) or ethanol (>32 mg/mL, ultrasonication). Do not use water as a solvent (APExBIO).
- Storage: Store lyophilized powder and DMSO/ethanol stock solutions below -20°C. Avoid repeated freeze-thaw cycles; use fresh solutions for experiments.
- Cellular assays: Optimal for use in GFP-FYVE HeLa and GFP-LCLC3 cell lines to monitor autophagy inhibition and vesicle trafficking changes.
- Concentration ranges: Effective Vps34 inhibition demonstrated at 1–100 nM in cellular models; higher concentrations (>10 μM) do not impact class I/II PI3Ks or mTOR (internal benchmarking).
- Synergistic studies: Combine with mTOR inhibitors (e.g., everolimus) to explore additive or synergistic effects on autophagy pathways.
Conclusion & Outlook
SAR405 sets a benchmark for selective autophagy inhibition by targeting Vps34 with nanomolar precision. It enables researchers to dissect autophagosome formation, lysosome function, and vesicle trafficking modulation without off-target interference. New insights into the AMPK-ULK1-Vps34 axis reveal that autophagy inhibition must be contextualized within the cell's energy status, refining the interpretation of SAR405's effects in disease models (Park et al., 2023). As research advances, SAR405 will remain a cornerstone for elucidating autophagy-related mechanisms in both cancer and neurodegenerative disease settings, provided its application parameters and mechanistic boundaries are respected.